Retail Pharmacies Fill Less than 2% of Mifepristone Orders

Why It Matters

The findings reveal that despite regulatory liberalization, retail pharmacy access to the abortion pill remains minimal, limiting convenient, in‑person options for many patients and highlighting ongoing legal and corporate barriers.

Key Takeaways

• Mail-order pharmacies fill ~2,700 mifepristone prescriptions monthly.
• Retail in‑store fills represent less than 2% of total fills.
• Independent pharmacies account for 92% of retail mifepristone sales.
• In 11 states with telehealth limits, retail fills rise to 61%.
• Chains CVS, Walgreens limited; Costco refuses to carry mifepristone.

Pulse Analysis

The FDA’s January 2023 decision to eliminate the in‑person dispensing requirement for mifepristone marked the most significant regulatory shift for medication abortion in decades. By moving the drug out of the Risk Evaluation and Mitigation Strategies (REMS) clinic‑only model, the agency opened the door for both brick‑and‑mortar and mail‑order pharmacies to fill prescriptions written by certified providers. Proponents argued that this would democratize access, especially in states where clinic networks are sparse, while opponents warned that broader availability could ignite new political battles. The change set the stage for a natural experiment in pharmacy‑based abortion care.

The University of Southern California’s recent JAMA analysis shows that the anticipated retail surge never materialized. Across the United States, pharmacies dispense roughly 2,700 mifepristone prescriptions each month, and more than 98% of those fills come from mail‑order channels in the 27 states and Washington, D.C. where abortion is legal and telehealth is permitted. In‑store pharmacies contributed less than 2% of total fills, with independent shops handling 92% of that modest share. Conversely, in the 11 states that restrict telehealth, retail pharmacies account for 61% of fills, highlighting how local regulations shape distribution patterns.

The data underscore both progress and persistent gaps. Mail‑order services provide privacy and convenience, yet they rely on stable internet access and mailing infrastructure—resources unavailable to many patients in rural or low‑income areas. The scant presence of major chains such as CVS, Walgreens, and the outright refusal by Costco suggest lingering corporate hesitancy, possibly driven by political pressure or liability concerns. Policymakers and advocacy groups may need to address these barriers through clearer guidance, shield‑law protections, and incentives for chain participation. Expanding reliable in‑store access could further reduce travel burdens and improve timely care in the post‑Dobbs landscape.